According to the South China Morning Post, Xian Jin, CEO of Hong Kong Science Park-based biotech startup Yicura BioMed, stated that the company plans to pursue an initial public offering (IPO) in Hong Kong as soon as feasible. He noted that Hong Kong's biotech ecosystem requires more "patient capital" as well as talent capable of commercializing research and development outcomes.